JPS6447715A - Improver for ovulation inductive pregnant genital physiological dysfunction - Google Patents

Improver for ovulation inductive pregnant genital physiological dysfunction

Info

Publication number
JPS6447715A
JPS6447715A JP20191987A JP20191987A JPS6447715A JP S6447715 A JPS6447715 A JP S6447715A JP 20191987 A JP20191987 A JP 20191987A JP 20191987 A JP20191987 A JP 20191987A JP S6447715 A JPS6447715 A JP S6447715A
Authority
JP
Japan
Prior art keywords
improver
tryptophan
genital
pregnant
ovulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP20191987A
Other languages
Japanese (ja)
Inventor
Katsuyoshi Oguro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resonac Holdings Corp
Original Assignee
Showa Denko KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Showa Denko KK filed Critical Showa Denko KK
Priority to JP20191987A priority Critical patent/JPS6447715A/en
Publication of JPS6447715A publication Critical patent/JPS6447715A/en
Pending legal-status Critical Current

Links

Abstract

PURPOSE:To obtain the titled pharmaceutical, containing L-tryptophan as an active ingredient, capable of inducing an increase in the number of human or animal ovulation without side effects, such as pregnant genital physiological dysfunction, especially abnormality by external stimulation, e.g. fetal cacogenesis. CONSTITUTION:An improver obtained by containing L-tryptophan which is one kind of essential amino acids contained in normal foods as an active ingredient. In use, the L-tryptophan can be used alone and in combination with other active ingredients. The improver is administered by any of methods for oral and parenteral administration. Intravenous, intramuscular and subcutaneous injections, etc., are cited as the parenteral administration. Continuous administration once a day for several days is effective in administering the improver, preferably in the anestrous or anaphrodisiac period once a day for 5-7 days. The dose thereof is 25-500mg/kg in the case of oral administration.
JP20191987A 1987-08-14 1987-08-14 Improver for ovulation inductive pregnant genital physiological dysfunction Pending JPS6447715A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP20191987A JPS6447715A (en) 1987-08-14 1987-08-14 Improver for ovulation inductive pregnant genital physiological dysfunction

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20191987A JPS6447715A (en) 1987-08-14 1987-08-14 Improver for ovulation inductive pregnant genital physiological dysfunction

Publications (1)

Publication Number Publication Date
JPS6447715A true JPS6447715A (en) 1989-02-22

Family

ID=16448974

Family Applications (1)

Application Number Title Priority Date Filing Date
JP20191987A Pending JPS6447715A (en) 1987-08-14 1987-08-14 Improver for ovulation inductive pregnant genital physiological dysfunction

Country Status (1)

Country Link
JP (1) JPS6447715A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874821A (en) * 1987-07-31 1989-10-17 Enichem Elastomeri S.P.A. Block copolymer and process for preparing it

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874821A (en) * 1987-07-31 1989-10-17 Enichem Elastomeri S.P.A. Block copolymer and process for preparing it

Similar Documents

Publication Publication Date Title
Yu et al. Role of endogenous interferon-γ on the enhancement of splenic NK cell activity by electroacupuncture stimulation in mice
ATE94393T1 (en) DOSE FORM FOR ORAL ADMINISTRATION OF HYPOGLYCAEMIC GLIPICIDE.
NO171145C (en) PROCEDURE FOR PREPARING A FAT EMULSION WITH A HYDROPHOBIC MEDICINE
IL99699A0 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
KR940018089A (en) Prevention and treatment for radiation damage of internal tissue
NZ229518A (en) Pharmaceutical dosage form for the medication of fish: method of administration and (prophylactic) treatment
MY109309A (en) Improvements in or relating to somatostatins
Memon et al. In vivo effects of interferon-alpha and interferon-gamma on lipolysis and ketogenesis
Yehuda et al. Thermoregulatory and locomotor effects of DSIP: paradoxical interaction with d-amphetamine
EP0414772A4 (en) Method for treating acne
EP0270026A3 (en) Pharmaceutical preparation comprising vitamin b6
KR910005858A (en) Fatty acid therapy
MY105798A (en) Treatment of leukocyte dysfunction with gm-csf.
PL370430A1 (en) Method of administering a thymosin alpha 1 peptide
JPS6447715A (en) Improver for ovulation inductive pregnant genital physiological dysfunction
MY106603A (en) Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
Lao et al. Electroacupuncture reduces morphine-induced emesis in ferrets: a pilot study
Cook Chemical immobilization of black bears in Great Smoky Mountains National Park
KR930003913A (en) Methods and pharmaceutical compositions for enhancing the antitussive effect of dextromethorphan
JPS6416721A (en) Antioxidant
ATE141510T1 (en) MEDICINAL PRODUCTS CONTAINING CD14
ATE91890T1 (en) MANUFACTURE OF A DRUG AGAINST ARTHRITIS AND RHEUMATISM.
Biskind The relation of nutritional deficiency to impaired libido and potency in the male
RU1803119C (en) Method of extrauterine pregnancy treatment
US3852456A (en) Method for controlling psoriasis